---
title: 'Molecularly guided therapy versus chemotherapy after disease control in unfavourable
  cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study'
date: '2024-08-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39096924/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240804182128&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Patients with unfavourable subset cancer of unknown primary
  (CUP) have a poor prognosis when treated with standard platinum-based chemotherapy.
  Whether first-line treatment guided by comprehensive genomic profiling (CGP) can
  improve outcomes is unknown. The CUPISCO trial was designed to inform a molecularly
  guided treatment strategy to improve outcomes over standard platinum-based chemotherapy
  in patients with newly diagnosed, unfavourable, non-squamous CUP. The aim of the
  trial ...'
disable_comments: true
---
BACKGROUND: Patients with unfavourable subset cancer of unknown primary (CUP) have a poor prognosis when treated with standard platinum-based chemotherapy. Whether first-line treatment guided by comprehensive genomic profiling (CGP) can improve outcomes is unknown. The CUPISCO trial was designed to inform a molecularly guided treatment strategy to improve outcomes over standard platinum-based chemotherapy in patients with newly diagnosed, unfavourable, non-squamous CUP. The aim of the trial ...